Next |
home / stock / vstm / vstm message board
Subject | By | Source | When |
---|---|---|---|
Happy I hit and run. I would consider | Harbor6460 | investorshub | 06/09/2023 4:06:50 PM |
$VSTM The gaining | Tartiaboy | investorshub | 06/08/2023 9:42:19 PM |
$VSTM news all the way baby | Tartiaboy | investorshub | 06/04/2023 12:16:39 PM |
They definite are diluting. They need money. | Harbor6460 | investorshub | 05/29/2023 2:44:48 PM |
highest volume in history -insert dd- | The Night Stalker | investorshub | 05/29/2023 5:53:28 AM |
$VSTM Time for this to show some returns | Harbor6460 | investorshub | 05/28/2023 5:08:47 PM |
Yep | Harbor6460 | investorshub | 05/26/2023 8:32:36 PM |
nice | knrorrel | investorshub | 05/26/2023 7:49:51 PM |
oh my | The Night Stalker | investorshub | 05/26/2023 7:37:35 PM |
Looks like dilution | Triple nickle | investorshub | 05/26/2023 7:28:31 PM |
Looks like real support at a dollar. Could | KeepOn | investorshub | 05/26/2023 6:37:35 PM |
Added the dip | Triple nickle | investorshub | 05/26/2023 6:10:34 PM |
I post so others can ride with me | Triple nickle | investorshub | 05/26/2023 5:26:57 PM |
$VSTM: Well, Capt. T-N, you certainly scored MONSTER | Invest-in-America | investorshub | 05/26/2023 5:23:00 PM |
Halted? | Harbor6460 | investorshub | 05/26/2023 5:15:06 PM |
Nice call | jchords | investorshub | 05/26/2023 4:57:04 PM |
Okay nice run folks | Triple nickle | investorshub | 05/26/2023 4:26:49 PM |
.75 comin up 1.00 soon | Triple nickle | investorshub | 05/26/2023 4:21:41 PM |
LV2 still looks real thin .75 ? | Triple nickle | investorshub | 05/26/2023 3:46:10 PM |
Really Good Friday here | Triple nickle | investorshub | 05/26/2023 3:44:18 PM |
News, Short Squeeze, Breakout and More Instantly...
Plan to announce topline RAMP 201 data with the start of planned rolling NDA submission for avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer in Q2 2024 FDA Fast Track Designation granted for avutometinib in combination with adagrasib for the treatment o...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 20...
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for ...